Addex Therapeutics Ltd
ADXN
$6.07
$0.132.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.35% | -40.19% | -- | -- | -99.02% |
| Total Other Revenue | -- | 376.92% | -- | 4,837.50% | -100.00% |
| Total Revenue | 1,064.71% | -8.15% | -65.41% | -70.60% | -99.02% |
| Cost of Revenue | -11.16% | 20.73% | -24.25% | -38.09% | -55.79% |
| Gross Profit | 36.31% | -32.19% | 3.11% | -708.55% | -1,421.82% |
| SG&A Expenses | 113.73% | 17.53% | -13.19% | -34.83% | -47.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.44% | 18.49% | -16.88% | -35.61% | -48.99% |
| Operating Income | -92.23% | -20.98% | 10.66% | 25.18% | 38.44% |
| Income Before Tax | -69.39% | -11.64% | -47.41% | -94.86% | -33.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.39% | -11.64% | -47.41% | -94.86% | -33.59% |
| Earnings from Discontinued Operations | 76.24% | -- | -99.10% | -- | 99.18% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.47% | -11.46% | -115.67% | 53.60% | 57.44% |
| EBIT | -92.23% | -20.98% | 10.66% | 25.18% | 38.44% |
| EBITDA | -103.06% | -32.35% | -1.80% | 25.17% | 41.50% |
| EPS Basic | -39.29% | 2.78% | -115.32% | 53.87% | 62.57% |
| Normalized Basic EPS | -41.86% | 2.68% | -45.10% | -92.59% | -17.81% |
| EPS Diluted | -39.29% | 2.78% | -115.32% | 53.87% | 62.57% |
| Normalized Diluted EPS | -41.86% | 2.68% | -45.10% | -92.59% | -17.81% |
| Average Basic Shares Outstanding | 19.88% | 14.62% | 2.26% | 0.83% | 13.90% |
| Average Diluted Shares Outstanding | 19.88% | 14.62% | 2.26% | 0.83% | 13.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |